Clinical trial • Phase I • Oncology
MDG1015 for Epithelial ovarian carcinoma | Myxoid (round cell) liposarcoma | Gastroesophageal junction adenocarcinoma | Synovial sarcoma
Phase I trial of MDG1015 for Epithelial ovarian carcinoma | Myxoid (round cell) liposarcoma | Gastroesophageal junction adenocarcinoma | Synovial sarcoma.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Epithelial ovarian carcinoma | Myxoid (round cell) liposarcoma | Gastroesophageal junction adenocarcinoma | Synovial sarcoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 28-11-2024
- First CTIS Authorization Date
- 01-04-2025
Trial design
Phase I trial across 2 sites in Netherlands.
- Target Sample Size
- 35
Eligibility
Recruits 35 Vulnerable population selected; no further details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected; no further details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 35
- Recruitment Window Months
- 204
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 20
Netherlands
- Earliest CTIS Part Ii Submission Date
- 26-03-2025
- Latest Decision Or Authorization Date
- 01-04-2025
- Processing Time Days
- 6
- Number Of Sites
- 2
- Number Of Participants
- 20
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Medical Oncology
- Contact Person Name
- Mathilde Jalving
- Contact Person Email
- m.jalving@umcg.nl
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medical Oncology
- Contact Person Name
- Sebastian Klobuch
- Contact Person Email
- s.klobuch@nki.nl
Sponsor
Primary sponsor
- Full Name
- Medigene AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- MDG1015
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)